GlassScriptPhysician profile
Bobby J Dupre
NPI 1164612479
$6,128.11
in general payments reported to CMS, 2019-2025
24 companies · $1,202 in 2025
The $1,202 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,393 · 2020: $580 · 2021: $145 · 2022: $479 · 2023: $614 · 2024: $714 · 2025: $1,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,530.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,035.31 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $556.76 | 2019-2023 | Amjevita, Avsola |
| Novartis Pharmaceuticals Corporation | $536.10 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $408.50 | 2019-2025 | Orencia |
| Ucb, INC. | $405.17 | 2019-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $312.89 | 2019-2025 | Benlysta |
| Pfizer INC. | $302.47 | 2019-2024 | |
| Horizon Therapeutics Plc | $277.97 | 2019-2021 | |
| Lilly USA, LLC | $176.69 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $140.52 | 2019 | |
| Genentech USA, INC. | $137.19 | 2019-2020 | |
| Medexus Pharma, INC. | $119.03 | 2019 | |
| Hikma Pharmaceuticals USA | $115.43 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $99.63 | 2019 | |
| Radius Health, INC. | $86.34 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $84.57 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $81.15 | 2023-2025 | Lupkynis |
| Celgene Corporation | $68.90 | 2019 | |
| Bioventus LLC | $50.05 | 2025 | Xcell |
| Mallinckrodt Hospital Products INC. | $47.88 | 2020 | |
| Fresenius Kabi USA, LLC | $35.96 | 2024-2025 | Idacio |
| Actelion Pharmaceuticals US, INC. | $22.07 | 2020 | |
| Genzyme Corporation | $20.84 | 2024 | |
| Organon LLC | $6.69 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bobby Dupre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.